open access

Vol 45, No 1 (2007)
Original paper
Submitted: 2011-12-19
Published online: 2007-03-24
Get Citation

CD40L and IL-4 stimulation of acute lymphoblastic leukemia cells results in upregulation of mRNA level of FLICE--an important component of apoptosis.

Włodzimierz łuczyński, Oksana Kowalczuk, Elibieta Iłendo, Anna Stasiak-Barmuta, Maryna Krawczuk-Rybak, Iwona Malinowska, Andrzej Kołtan, Tomasz Szczepalński, Igor Olejnik, Radosław Jaworowski, Lech Chyczewski, Michał Matysiak, Mariusz Wysocki, Danuta Sońta-Jakimczyk, Maria Wieczorek
Folia Histochem Cytobiol 2007;45(1):15-20.

open access

Vol 45, No 1 (2007)
ORIGINAL PAPERS
Submitted: 2011-12-19
Published online: 2007-03-24

Abstract

The use of cancer vaccines based on dendritic cells (DC) presenting tumor antigens can be a promising tool in the treatment of leukemia. The functional characteristics of leukemia derived DC is still to be elucidated. CD40 promotes survival, proliferation and differentiation of normal B cells. CD40 triggering was used to enhance the poor antigen-presenting capacity of leukemic B-cells. Since it is still unclear whether CD40 ligation drives neoplastic B-cells to apoptosis or not, we assessed the mRNA expression of FLICE, FAS, FADD and TRADD - important components of apoptosis machinery, using real-time PCR in acute lymphoblastic leukemia cells before and after CD40 and IL-4 stimulation. ALL cells stimulated with CD40L/IL-4 expressed dendritic cell phenotype at mRNA and protein levels (upregulation of main costimulatory and adhesion molecules noted in real-time RT PCR and flow cytometry); they also expressed higher amounts of mRNA for FLICE, TRADD and FADD after CD40L/IL-4 stimulation. However differences statistically significant comparing cells cultured with CD40L/IL-4 and medium alone regarded only FLICE. Concluding, we showed upregulation of important elements of apoptosis at mRNA level in ALL cells after CD40 ligation.

Abstract

The use of cancer vaccines based on dendritic cells (DC) presenting tumor antigens can be a promising tool in the treatment of leukemia. The functional characteristics of leukemia derived DC is still to be elucidated. CD40 promotes survival, proliferation and differentiation of normal B cells. CD40 triggering was used to enhance the poor antigen-presenting capacity of leukemic B-cells. Since it is still unclear whether CD40 ligation drives neoplastic B-cells to apoptosis or not, we assessed the mRNA expression of FLICE, FAS, FADD and TRADD - important components of apoptosis machinery, using real-time PCR in acute lymphoblastic leukemia cells before and after CD40 and IL-4 stimulation. ALL cells stimulated with CD40L/IL-4 expressed dendritic cell phenotype at mRNA and protein levels (upregulation of main costimulatory and adhesion molecules noted in real-time RT PCR and flow cytometry); they also expressed higher amounts of mRNA for FLICE, TRADD and FADD after CD40L/IL-4 stimulation. However differences statistically significant comparing cells cultured with CD40L/IL-4 and medium alone regarded only FLICE. Concluding, we showed upregulation of important elements of apoptosis at mRNA level in ALL cells after CD40 ligation.
Get Citation
About this article
Title

CD40L and IL-4 stimulation of acute lymphoblastic leukemia cells results in upregulation of mRNA level of FLICE--an important component of apoptosis.

Journal

Folia Histochemica et Cytobiologica

Issue

Vol 45, No 1 (2007)

Article type

Original paper

Pages

15-20

Published online

2007-03-24

Bibliographic record

Folia Histochem Cytobiol 2007;45(1):15-20.

Authors

Włodzimierz łuczyński
Oksana Kowalczuk
Elibieta Iłendo
Anna Stasiak-Barmuta
Maryna Krawczuk-Rybak
Iwona Malinowska
Andrzej Kołtan
Tomasz Szczepalński
Igor Olejnik
Radosław Jaworowski
Lech Chyczewski
Michał Matysiak
Mariusz Wysocki
Danuta Sońta-Jakimczyk
Maria Wieczorek

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl